Not all people with CLL demand therapy. In spite of all recent innovations, the iwCLL nevertheless endorses watchful observation for individuals with asymptomatic condition.86 This recommendation is based on at least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 The two trials concluded https://carlosm530jrz7.myparisblog.com/profile